CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Background The 5 ‐ fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first‐line treatment for metastatic colorectal cancer (mCRC), however, the optimal second‐line regimen for KRAS wild‐type mCRC patients is still investigational. In this study, we aimed to determine the clinical efficacy and safety of CMAB009 plus irinotecan compared to irinotecan‐only as a second‐line regimen for treating KRAS wild‐type mCRC patients....